Bu sayfada
IOVA Iovance Biotherapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 6, 2026
$14,22
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$1,7652 haftanın en düşüğü
$15,3052 haftanın en yükseği
Piyasa Değeri (MRQ)
$6.44B
P/E
-13.0
Hisse Başına Kâr
$-1.09
Gelir
$264M
rozetleriniz
52 Haftlık Aralık
$2–$15
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$12
P/E
-13.0
ROE
-56.0%
Net Kâr Marjı
-89.1%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
IOVA Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$14.21
Piyasa Değeri (MRQ)
$6.44B
P/E
-13.0
Hisse Başına Kâr
$-1.09
Gelir
$264M
ROE
-56.0%
D/E Borç/Özsermaye
0.0
52 Haftlık Aralık
$2–$15
IOVA Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 26 Eylül 2013 | 1-for-100 | Ters |
Iovance Biotherapeutics, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Iovance Biotherapeutics, Inc. is a biopharmaceutical company based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
## History
The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became Lion Bio Pharma, which was then rebranded to Iovance in 2017.
In 2024, the US FDA gave accelerated approval to Lifileucel, marketed under the brand name Amtagvi, the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma.
TIL monotherapy and TIL combination therapies are being investigated by Iovance in multiple clinical studies in multiple advanced solid tumor cancers such as NSCLC and sarcoma.
TIL therapy is manufactured at their 136,000–square-foot Cell Therapy Center, located in Philadelphia, PA, using proprietary good manufacturing practices (GMP).
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriBiotechnology
çalışanlar975
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$264M2016-12-31 → 2025-12-31
Hisse Başına Kâr$-1.092019-12-31 → 2025-12-31
Serbest Nakit Akışı$-336M2016-12-31 → 2025-12-31
Net kar marjı-89.1%2023-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | IOVA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E | -13.05Y ort. ≈-4.7 | ≈-4.7 | · | · | |
| F/S (TTM) | 19.85Y ort. ≈589.8 | ≈589.8 | 31.8 | Düşük değerli | |
| F/D (MRQ) | 8.75Y ort. ≈3.1 | ≈3.1 | 9.0 | Düşük değerli | |
| EV / EBITDA | -14.2 | · | · | · | |
| Fiyat / Serbest Nakit Akışı (TTM) | -21.75Y ort. ≈-6.0 | ≈-6.0 | · | · | |
| Fiyat / Nakit Akışı (TTM) | -24.45Y ort. ≈-6.6 | ≈-6.6 | · | · | |
| EV / Revenue (EV / Gelir) | 21.1 | · | · | · | |
| EV / FCF | -16.5 | · | · | · | |
| Fiyat / Maddi Defter Değeri (MRQ) | 13.65Y ort. ≈4.2 | ≈4.2 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | IOVA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | -92.7%5Y ort. ≈-13043.0% | ≈-13043.0% | -68.1% | En üst düzey | |
| FAVÖK Marjı (TTM) | -88.6%5Y ort. ≈-12714.6% | ≈-12714.6% | -68.1% | En üst düzey | |
| Vergi Öncesi Kar Marjı (TTM) | -90.4%5Y ort. ≈-12671.9% | ≈-12671.9% | -68.6% | En üst düzey | |
| Net Kâr Marjı (TTM) | -89.1%5Y ort. ≈-12573.5% | ≈-12573.5% | -157.9% | En üst düzey | |
| ROA | -42.9%5Y ort. ≈-49.5% | ≈-49.5% | -22.4% | Zayıf | |
| ROE | -56.0%5Y ort. ≈-63.4% | ≈-63.4% | -56.0% | Aynı seviyede | |
| ROIC | -57.4%5Y ort. ≈-63.6% | ≈-63.6% | -23.2% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | IOVA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Debt / Equity (Borç / Öz Sermaye) | 0.0 | · | 0.8 | Düşük borç | |
| Cari Oran (MRQ) | 4.35Y ort. ≈4.1 | ≈4.1 | 7.3 | Düşük likidite | |
| Cari Oran (MRQ) | 3.75Y ort. ≈3.9 | ≈3.9 | 3.7 | Aynı seviyede |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | IOVA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 60.6% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | IOVA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.35Y ort. ≈0.2 | ≈0.2 | 0.0 | En üst düzey | |
| Inventory Turnover (Stok Devir Hızı) | 3.45Y ort. ≈3.1 | ≈3.1 | · | · | |
| Receivables Turnover (Alacak Devir Hızı) | 3.55Y ort. ≈8.0 | ≈8.0 | 7.9 | Zayıf | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$270.3K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-11.5%
Sonraki Rapor
Kas 04, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 6, 2026 | $-0.11 | $-0.13 | 14.3% |
| 31 Mart 2026 | May 7, 2026 | $-0.19 | $-0.15 | -24.3% |
| 31 Aralık 2025 | $-0.18 | $-0.18 | -2.8% | |
| 30 Eylül 2025 | $-0.25 | $-0.26 | 5.0% | |
| 30 Haziran 2025 | $-0.33 | $-0.29 | -13.7% | |
| 31 Mart 2025 | $-0.36 | $-0.24 | -47.5% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $264M | $164M | $1M | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $173M | $93M | $1M | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $300M | $276M | $333M | $295M | $259M | $202M | $166M | $100M | $72M | $27M | $15M | $4M | |
| SG&A Expense | $152M | $152M | $106M | $104M | $84M | $60M | $41M | $28M | $21M | $27M | $12M | $8M | |
| Operating Expenses | $667M | $559M | $462M | $399M | $343M | $262M | $207M | $128M | $93M | $54M | $28M | $12M | |
| Operating Income | $-403M | $-395M | $-461M | $-399M | $-343M | $-262M | $-207M | $-128M | $-93M | $-54M | $-28M | $-12M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $-5.7K | |
| Interest Income | $10M | $20M | $13M | $3M | $451.0K | $2M | $9M | $5M | $813.0K | $745.0K | $200.0K | $6.0K | |
| Other Non-op | · | · | · | · | · | · | · | · | · | · | $200.0K | $6.0K | |
| Pretax Income | $-393M | $-375M | $-448M | $-396M | $-342M | · | · | · | · | · | · | · | |
| Income Tax | $-2M | $-3M | $-3M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-391M | $-372M | $-444M | $-396M | $-342M | $-260M | $-198M | $-124M | $-92M | $-53M | $-28M | $-12M | |
| EPS (Basic) | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 | $-1.88 | $-1.59 | · | · | · | · | · | |
| EPS (Diluted) | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 | $-1.88 | $-1.59 | · | · | · | · | · | |
| Shares (Basic) | 357,345 | 289,877 | 235,131 | 159,259 | 153,406 | 138,301 | 124,336 | · | · | · | · | · | |
| Shares (Diluted) | 357,345 | 289,877 | 235,131 | 159,259 | 153,406 | 138,301 | 124,336 | · | · | · | · | · | |
| EBITDA | $-390M | $-383M | $-449M | $-390M | $-340M | $-261M | $-206M | $-128M | $-93M | $-54M | $-28M | · |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $163M | $116M | $115M | $232M | $78M | $67M | $14M | $82M | $145M | $107M | $34M | $45M | |
| Short-term Investments | $134M | $208M | $165M | $240M | $426M | $562M | $293M | $386M | $0 | $60M | $70M | $0 | |
| Receivables | $82M | $69M | $151.0K | · | · | · | · | · | · | · | · | · | |
| Inventory | $52M | $52M | $10M | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $12M | $12M | $17M | $7M | $4M | $7M | $9M | $7M | $4M | $3M | $277.0K | $66.0K | |
| Current Assets | $443M | $457M | $308M | $479M | $508M | $636M | $316M | $475M | $149M | $170M | $104M | $45M | |
| PP&E (Net) | $131M | $109M | $114M | $105M | $101M | $59M | $9M | $3M | $2M | $2M | $2M | $2M | |
| PP&E (Gross) | $180M | $145M | $142M | $122M | $110M | $65M | $13M | $7M | $5M | $4M | $3M | $2M | |
| Accum. Depreciation | $49M | $36M | $28M | $17M | $9M | $6M | $4M | $4M | $3M | $2M | $1M | $104.0K | |
| Intangibles | $279M | $282M | $229M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $8M | $369.0K | $270.0K | $189.0K | $2M | $13M | $3M | $3M | $4M | $0 | · | · | |
| Total Assets | $913M | $910M | $780M | $664M | $777M | $768M | $345M | $481M | $155M | $172M | $106M | $47M | |
| Accounts Payable | $22M | $28M | $33M | $27M | $27M | $14M | $16M | $3M | $1M | $863.0K | $958.0K | $1M | |
| Accrued Liabilities | $111M | $82M | $69M | $52M | $57M | $35M | $16M | $12M | $8M | $4M | $672.0K | $328.0K | |
| Short-term Debt | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $138M | $122M | $110M | $91M | $89M | $55M | $39M | $14M | $10M | $5M | $2M | $2M | |
| Capital Leases | $44M | $44M | $67M | $72M | $65M | $45M | $4M | $0 | · | · | · | · | |
| Deferred Tax | $32M | $32M | $17M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | $12M | $2M | $230.0K | · | · | · | · | |
| Total Liabilities | $215M | $200M | $196M | $164M | $156M | $112M | $46M | $15M | $10M | · | · | · | |
| Total Debt | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $17.0K | $13.0K | $11.0K | $8.0K | $7.0K | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $2.0K | $2.0K | |
| Paid-in Capital | $3.46B | $3.10B | $2.59B | $2.07B | $1.79B | $1.49B | $869M | $839M | $395M | $324M | $208M | $121M | |
| Retained Earnings | $-2.78B | $-2.38B | $-2.01B | $-1.57B | $-1.17B | $-830M | $-571M | $-373M | $-249M | $-157M | $-104M | $-77M | |
| AOCI | $16M | $-1M | $3M | $-902.0K | $-601.0K | $19.0K | $220.0K | $-42.0K | $0 | $29.0K | $48.0K | $0 | |
| Stockholders' Equity | $699M | $710M | $585M | $500M | $622M | $656M | $299M | $466M | $145M | $167M | $104M | $45M | |
| Liabilities + Equity | $913M | $910M | $780M | $664M | $777M | $768M | $345M | $481M | $155M | $172M | $106M | $47M | |
| Shares Outstanding | 411,938,061 | 305,252,194 | 256,135,715 | 187,812,072 | 157,004,742 | 147,874,917 | 126,411,808 | 123,415,576 | 73,164,914 | 62,248,074 | 48,547,720 | 33,750,188 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $13M | $11M | $12M | $9M | $3M | $1M | $1M | $956.0K | $952.0K | $978.0K | $999.0K | $88.0K | |
| Stock-based Comp | $62M | $110M | $63M | $84M | $70M | $41M | $24M | $20M | $12M | $19M | $9M | $4M | |
| Deferred Tax | $-2M | $-3M | $-3M | · | · | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $23M | $26M | $10M | $0 | · | · | · | · | · | · | · | · | |
| Restructuring | $5M | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | $16M | $-100M | $12M | $10M | $41M | $12M | $13M | · | · | · | · | · | |
| Operating Cash Flow | $-302M | $-353M | $-362M | $-293M | $-228M | $-205M | $-159M | $-101M | $-79M | $-33M | $-18M | $-9M | |
| CapEx | $34M | $11M | $22M | $20M | $38M | $47M | $7M | $1M | $1M | $2M | $1M | $2M | |
| Investing Cash Flow | $47M | $-96M | $-155M | $256M | $132.0K | $-318M | $90M | $-386M | $59M | $9M | $-71M | · | |
| Debt Issued | · | · | · | · | $1M | · | · | · | · | · | · | · | |
| Net Debt Issued | · | · | · | · | $1M | · | · | · | · | · | · | · | |
| Stock Issued | $306M | $397M | $463M | $190M | $203M | $567M | · | $399M | $54M | $96M | $68M | $32M | |
| Net Stock Activity | $306M | $397M | $463M | $190M | $203M | $567M | · | $399M | $54M | $96M | $68M | · | |
| Financing Cash Flow | $301M | $391M | $463M | $190M | $239M | $576M | $6M | $424M | $59M | $97M | $78M | · | |
| Net Change in Cash | $47M | $-59M | $-57M | $154M | $11M | · | · | $-63M | $39M | $73M | $-11M | $25M | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Free Cash Flow | $-336M | $-364M | $-384M | $-313M | $-266M | $-252M | $-166M | $-102M | $-80M | $-34M | $-20M | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -153.1% | -240.9% | -38735.0% | · | · | · | · | · | · | · | · | · | |
| Net Margin | -148.4% | -226.8% | -37345.4% | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | -149.2% | -228.6% | -37638.0% | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -148.2% | -233.6% | -37762.1% | · | · | · | · | · | · | · | · | · | |
| ROA | -42.9% | -44.0% | -61.5% | -54.9% | -44.3% | -46.6% | -47.9% | -38.9% | -56.3% | -38.1% | -36.4% | · | |
| ROE | -56.0% | -50.2% | -70.6% | -88.6% | -51.9% | -37.9% | -60.4% | -34.3% | -58.9% | -39.0% | -37.2% | · | |
| ROIC | -57.4% | -55.2% | -78.2% | · | · | · | · | · | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.7 | 2.8 | 5.2 | 5.7 | 11.6 | 8.1 | 33.0 | 15.1 | 34.1 | 63.8 | · | |
| Quick Ratio | 2.7 | 3.2 | 2.5 | 5.2 | 5.7 | 11.5 | 7.9 | 32.5 | 14.7 | 33.5 | 51.4 | · | |
| Debt / Equity | 0.0 | · | · | · | · | · | · | · | · | · | · | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | 0.0 | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 3.4 | 4.0 | 2.1 | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 3.5 | 4.7 | 15.7 | · | · | · | · | · | · | · | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.70 | $2.33 | $2.28 | $2.66 | $3.96 | $4.47 | $2.37 | $3.78 | $1.99 | $2.68 | $2.14 | · | |
| Revenue / Share | $737.39 | $566.00 | $5.06 | · | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-846.26 | $-1217.68 | $-1538.80 | $-1838.24 | $-1485.87 | · | · | · | · | · | · | · | |
| Cash / Share | $0.40 | $0.38 | $0.45 | $1.23 | $0.50 | $0.46 | $0.11 | $0.67 | $1.99 | $1.71 | $0.28 | · | |
| EPS (TTM) | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 | $-1.88 | $-1.59 | · | · | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 60.6% | 13699.0% | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $264M | $164M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income TTM | $-391M | $-372M | $-444M | $-396M | $-342M | $-260M | $-198M | $-124M | $-92M | $-53M | $-28M | $-12M | |
| Market Cap | $1.12B | $2.26B | $2.08B | $1.20B | $3.00B | $6.81B | $3.50B | $1.09B | $585M | $433M | $375M | · | |
| Enterprise Value | $829M | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -2.5 | -5.8 | -4.3 | -2.6 | -8.6 | -24.7 | -17.4 | · | · | · | · | · | |
| P/S | 4.3 | 13.8 | 1751.4 | · | · | · | · | · | · | · | · | · | |
| P/B | 1.6 | 3.2 | 3.6 | 2.4 | 4.8 | 10.4 | 11.7 | 2.3 | 4.0 | 2.6 | 3.6 | · | |
| P / Tangible Book | 2.7 | 5.3 | 5.9 | 2.4 | 4.8 | 10.4 | · | · | · | · | · | · | |
| P / Cash Flow | -3.7 | -6.4 | -5.8 | -4.1 | -13.1 | -33.2 | -22.0 | -10.8 | -7.4 | -13.2 | -20.4 | · | |
| P / FCF | -3.3 | -6.2 | -5.4 | -3.8 | -11.3 | -27.1 | -21.1 | -10.7 | -7.3 | -12.7 | -19.2 | · | |
| EV / EBITDA | -2.1 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | -2.5 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 3.1 | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -39.9% | -17.3% | -23.2% | -39.0% | -11.7% | -4.0% | -5.7% | · | · | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $99M | $71M | $87M | $67M | $60M | $49M | $74M | $59M | $31M | $715.0K | $482.0K | $469.0K | $238.0K | · | · | · | |
| Cost of Revenue | $44M | $42M | $28M | $38M | $49M | $43M | $23M | $32M | $31M | $7M | $-5M | $4M | $2M | · | · | · | |
| R&D Expense | $59M | $62M | $69M | $75M | $78M | $76M | $67M | $67M | $62M | $80M | $77M | $88M | $86M | $83M | $73M | $73M | |
| SG&A Expense | $39M | $39M | $36M | $35M | $38M | $44M | $42M | $39M | $40M | $31M | $29M | $27M | $22M | $28M | $28M | $26M | |
| Operating Expenses | $151M | $152M | $160M | $162M | $174M | $171M | $160M | $148M | $133M | $118M | $122M | $119M | $110M | $111M | $100M | $100M | |
| Operating Income | $-52M | $-81M | $-73M | $-95M | $-114M | $-121M | $-87M | $-89M | $-102M | $-118M | $-121M | $-118M | $-110M | $-111M | $-100M | $-100M | |
| Interest Income | $3M | $1M | $2M | $1M | $4M | $3M | $10M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | $777.0K | $385.0K | |
| Pretax Income | $-49M | $-80M | $-72M | $-94M | $-110M | $-118M | $-77M | $-85M | $-99M | $-114M | $-118M | $-115M | $-107M | $-107M | $-100M | $-99M | |
| Income Tax | $-1M | $-665.0K | $184.0K | $-2M | $2M | $-2M | $2M | $-2M | $-1M | $-1M | $-2M | $-1M | $-477.0K | $0 | · | · | |
| Net Income | $-47M | $-79M | $-72M | $-91M | $-112M | $-116M | $-79M | $-84M | $-97M | $-113M | $-116M | $-114M | $-107M | $-107M | $-100M | $-99M | |
| EPS (Basic) | $-0.11 | $-0.19 | $-0.15 | $-0.25 | $-0.33 | $-0.36 | $-0.24 | $-0.28 | $-0.34 | $-0.42 | $-0.46 | $-0.46 | $-0.47 | $-0.50 | $-0.63 | $-0.63 | |
| EPS (Diluted) | $-0.11 | $-0.19 | · | · | $-0.33 | $-0.36 | $-0.24 | $-0.28 | $-0.34 | $-0.42 | $-0.46 | $-0.46 | $-0.47 | $-0.50 | $-0.63 | $-0.63 | |
| Shares (Basic) | 450,189 | 418,511 | · | 364,037 | 334,511 | 322,868 | · | 303,269 | 284,817 | 266,220 | · | 245,817 | 224,481 | 213,694,000 | 157,817,000 | 157,274,000 | |
| Shares (Diluted) | 450,189 | 418,511 | · | · | 334,511 | 322,868 | · | 303,269 | 284,817 | 266,220 | · | 245,817 | 224,481 | 213,694,000 | 157,817,000 | 157,274,000 | |
| EBITDA | $-52M | $-78M | · | $-95M | $-110M | $-118M | · | $-86M | $-99M | $-115M | · | $-115M | $-107M | $-108M | $-100M | $-100M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $111M | $197M | $163M | $158M | $132M | $172M | $116M | $164M | $229M | $134M | $115M | $268M | $230M | $543M | $118M | $108M | |
| Short-term Investments | $187M | $117M | $134M | $143M | $169M | $188M | $208M | $233M | $184M | $222M | · | $94M | $21M | $83M | $242M | $316M | |
| Receivables | $102M | $82M | $82M | $67M | $60M | $71M | $69M | $56M | $32M | $234.0K | · | · | $33.0K | · | · | · | |
| Inventory | $56M | $58M | $52M | $52M | $50M | $66M | $52M | $39M | $28M | $18M | · | $9M | $10M | · | · | · | |
| Prepaid Expense | $9M | $13M | $12M | $10M | $12M | $16M | $12M | $7M | $10M | $11M | · | $12M | $14M | $11M | $10M | $7M | |
| Current Assets | $464M | $467M | $443M | $429M | $422M | $513M | $457M | $499M | $482M | $386M | · | $383M | $275M | $638M | $370M | $432M | |
| PP&E (Net) | $131M | $131M | $131M | $127M | $122M | $112M | $109M | $113M | $111M | $112M | · | $113M | $113M | $110M | $101M | $101M | |
| PP&E (Gross) | $188M | $184M | $180M | $172M | $165M | $150M | $145M | $149M | $145M | $143M | · | $138M | $135M | $129M | $115M | $113M | |
| Accum. Depreciation | $56M | $52M | $49M | $45M | $42M | $39M | $36M | $37M | $34M | $31M | · | $25M | $22M | $19M | $14M | $11M | |
| Intangibles | $264M | $269M | $279M | $285M | $296M | $285M | $282M | $307M | $295M | $294M | · | $224M | $236M | · | · | · | |
| Other Non-current Assets | $6M | $8M | $8M | $9M | $10M | $426.0K | $369.0K | $280.0K | $327.0K | $259.0K | · | $282.0K | $294.0K | $202.0K | $596.0K | $856.0K | |
| Total Assets | $916M | $926M | $913M | $905M | $907M | $967M | $910M | $991M | $964M | $870M | · | $852M | $757M | $825M | $546M | $611M | |
| Accounts Payable | $26M | $37M | $22M | $31M | $32M | $28M | $28M | $32M | $20M | $26M | · | $19M | $31M | $32M | $24M | $20M | |
| Accrued Liabilities | $78M | $88M | $111M | $87M | $89M | $85M | $82M | $75M | $62M | $46M | · | $61M | $47M | $43M | $48M | $38M | |
| Short-term Debt | · | $1M | $1M | $1M | $1M | $1M | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $107M | $129M | $138M | $126M | $129M | $123M | $122M | $118M | $94M | $83M | · | $91M | $89M | $87M | $79M | $64M | |
| Capital Leases | $43M | $44M | $44M | $45M | $45M | $44M | $44M | $66M | $69M | $72M | · | $68M | $69M | $70M | $72M | $73M | |
| Deferred Tax | $29M | $31M | $32M | $32M | $35M | $32M | $32M | $32M | $32M | $33M | · | $18M | $20M | · | · | · | |
| Total Liabilities | $179M | $204M | $215M | $203M | $209M | $199M | $200M | $218M | $196M | $190M | · | $178M | $179M | $158M | $152M | $138M | |
| Total Debt | · | $1M | · | $1M | $1M | $1M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $19.0K | $18.0K | $17.0K | $16.0K | $14.0K | $14.0K | $13.0K | $13.0K | $12.0K | $12.0K | · | $11.0K | $9.0K | $9.0K | $7.0K | $7.0K | |
| Paid-in Capital | $3.62B | $3.56B | $3.46B | $3.39B | $3.29B | $3.26B | $3.10B | $3.06B | $2.99B | $2.81B | · | $2.58B | $2.36B | $2.34B | $1.86B | $1.84B | |
| Retained Earnings | $-2.90B | $-2.85B | $-2.78B | $-2.70B | $-2.61B | $-2.50B | $-2.38B | $-2.31B | $-2.22B | $-2.13B | · | $-1.90B | $-1.78B | $-1.68B | $-1.46B | $-1.36B | |
| AOCI | $13M | $13M | $16M | $16M | $21M | $6M | $-1M | $16M | $526.0K | $116.0K | · | $-9M | $325.0K | $-126.0K | $-2M | $-3M | |
| Stockholders' Equity | $736M | $722M | $699M | $702M | $698M | $768M | $710M | $773M | $769M | $680M | $585M | $674M | $579M | $667M | $394M | $473M | |
| Liabilities + Equity | $916M | $926M | $913M | $905M | $907M | $967M | $910M | $991M | $964M | $870M | · | $852M | $757M | $825M | $546M | $611M | |
| Shares Outstanding | 452,971,016 | 438,106,537 | 411,938,061 | 385,461,728 | 341,919,364 | 333,934,387 | 305,252,194 | 304,620,470 | 297,305,999 | 279,756,339 | · | 255,833,679 | 224,688,434 | 224,358,979 | 157,840,581 | 157,800,581 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $4M | $3M | $3M | $3M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | |
| Stock-based Comp | $12M | $11M | $12M | $12M | $15M | $23M | $31M | $31M | $30M | $17M | $14M | $16M | $17M | $16M | $20M | $22M | |
| Deferred Tax | $-1M | $-665.0K | $184.0K | $-2M | $2M | $-2M | $2M | $-2M | $-1M | $-1M | $-2M | $-1M | $-477.0K | $0 | $0 | · | |
| Amort. of Intangibles | $6M | $6M | $6M | $6M | $6M | $5M | $11M | $6M | $6M | $5M | $4M | $4M | $2M | $0 | $0 | $0 | |
| Restructuring | · | · | $0 | $5M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-6M | · | · | · | $-11M | · | · | · | $-28M | · | · | · | $-11M | · | · | |
| Operating Cash Flow | $-61M | $-72M | $-53M | $-79M | $-67M | $-104M | $-73M | $-59M | $-98M | $-122M | $-84M | $-84M | $-94M | $-100M | $-64M | $-78M | |
| CapEx | $5M | $7M | $9M | $11M | $7M | $6M | $4M | $2M | $442.0K | $4M | $4M | $4M | $10M | $6M | $1M | $5M | |
| Investing Cash Flow | $-74M | $11M | $775.0K | $17M | $14M | $16M | $24M | $-49M | $40M | $-112M | $-73M | $-79M | $-157M | $153M | $74M | $96M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Stock Issued | $50M | $99M | $56M | $89M | $13M | $149M | $0 | $48M | $152M | $198M | $1.0K | $203M | $0 | $260M | $0 | $0 | |
| Net Stock Activity | · | $99M | · | · | · | $149M | · | · | · | $198M | · | · | · | $260M | · | · | |
| Financing Cash Flow | $49M | $94M | $56M | $88M | $13M | $143M | $2M | $42M | $153M | $194M | $962.0K | $203M | $1M | $258M | $225.0K | $-2M | |
| Net Change in Cash | $-86M | $33M | $5M | $26M | $-40M | $56M | $-48M | $-65M | $94M | $-41M | $-153M | $38M | $-253M | $312M | $10M | · | |
| Free Cash Flow | · | $-79M | · | · | · | $-110M | · | · | · | $-126M | · | · | · | $-105M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -52.3% | -113.5% | · | -140.7% | -189.8% | -245.8% | · | -152.1% | -327.6% | -16464.6% | · | -25236.9% | -46254.6% | · | · | · | |
| Net Margin | -47.6% | -110.7% | · | -135.3% | -186.2% | -235.5% | · | -142.7% | -312.2% | -15800.8% | · | -24255.9% | -44759.7% | · | · | · | |
| Pretax Margin | -49.0% | -111.6% | · | -138.8% | -182.9% | -239.2% | · | -145.3% | -316.8% | -15997.8% | · | -24520.9% | -44960.1% | · | · | · | |
| EBITDA Margin | -52.3% | -109.5% | · | -140.7% | -184.1% | -240.1% | · | -147.0% | -318.0% | -16048.1% | · | -24618.5% | -45036.1% | · | · | · | |
| ROA | -5.2% | -8.3% | · | -9.6% | -11.9% | -12.7% | · | -9.1% | -11.3% | -13.3% | · | -16.3% | -15.6% | -14.1% | -14.5% | -13.6% | |
| ROE | -6.6% | -10.6% | · | -12.4% | -15.2% | -16.1% | · | -11.5% | -14.4% | -16.8% | · | -21.3% | -20.3% | -17.6% | -18.2% | -16.3% | |
| ROIC | -6.9% | -11.1% | · | -13.2% | -16.6% | -15.5% | · | -11.3% | -13.1% | -17.1% | · | -17.4% | -18.9% | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.3 | 3.6 | · | 3.4 | 3.3 | 4.2 | · | 4.2 | 5.2 | 4.6 | · | 4.2 | 3.1 | 7.3 | 4.7 | 6.7 | |
| Quick Ratio | 3.7 | 3.1 | · | 2.9 | 2.8 | 3.5 | · | 3.8 | 4.7 | 4.3 | · | 4.0 | 2.8 | 7.2 | 4.5 | 6.6 | |
| Debt / Equity | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.0 | 0.0 | · | 0.0 | 0.0 | · | · | · | |
| Inventory Turnover | 0.8 | 0.7 | · | 0.9 | 1.5 | 1.2 | · | 1.7 | 1.7 | 0.8 | · | 0.9 | 0.4 | · | · | · | |
| Receivables Turnover | 1.2 | 0.9 | · | 1.1 | 1.3 | 1.4 | · | 2.1 | 2.0 | 6.1 | · | · | 14.4 | · | · | · |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.62 | $1.65 | · | $1.82 | $2.04 | $2.30 | · | $2.54 | $2.58 | $2.43 | · | $2.63 | $2.58 | $2.97 | $2.49 | $3.00 | |
| Revenue / Share | $220.60 | $170.68 | · | · | $179.22 | $152.77 | · | $193.08 | $109.21 | $0.00 | · | $0.00 | $0.00 | · | · | · | |
| Cash Flow / Share | · | $-172.22 | · | · | · | $-321.17 | · | · | · | $-0.46 | · | · | · | $-0.47 | · | · | |
| Cash / Share | $0.24 | $0.45 | · | $0.41 | $0.39 | $0.51 | · | $0.54 | $0.77 | $0.48 | · | $1.05 | $1.02 | $2.42 | $0.75 | $0.68 | |
| EPS (TTM) | · | · | · | $-1.21 | $-1.21 | $-1.22 | · | $-1.50 | $-1.68 | $-1.81 | · | $-2.08 | $-2.25 | $-2.41 | $-2.48 | $-2.40 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $325M | $286M | · | $250M | $242M | $213M | · | $91M | $33M | $2M | · | · | · | $0 | $0 | $0 | |
| Net Income TTM | $-290M | $-354M | · | $-398M | $-390M | $-375M | · | $-410M | $-440M | $-450M | · | $-433M | $-419M | $-412M | $-390M | $-376M | |
| Market Cap | $1.88B | $1.54B | · | $836M | $588M | $1.11B | · | $2.86B | $2.38B | $4.15B | · | $1.16B | $1.58B | $1.37B | $1.51B | $1.74B | |
| Enterprise Value | · | $1.23B | · | $537M | $288M | $753M | · | · | · | · | · | · | · | · | · | · | |
| P/E | · | · | · | -1.8 | -1.4 | -2.7 | · | -6.3 | -4.8 | -8.2 | · | -2.2 | -3.1 | -2.5 | -3.9 | -4.6 | |
| P/S | 5.8 | 5.4 | · | 3.3 | 2.4 | 5.2 | · | 31.5 | 72.8 | 2177.5 | · | · | · | · | · | · | |
| P/B | 2.6 | 2.1 | · | 1.2 | 0.8 | 1.4 | · | 3.7 | 3.1 | 6.1 | · | 1.7 | 2.7 | 2.1 | 3.8 | 3.7 | |
| P / Tangible Book | 4.0 | 3.4 | · | 2.0 | 1.5 | 2.3 | · | 6.1 | 5.0 | 10.7 | · | 2.6 | 4.6 | 2.1 | 3.8 | 3.7 | |
| P / Cash Flow | · | -21.3 | · | · | · | -10.7 | · | · | · | -33.9 | · | · | · | -13.7 | · | · | |
| EV / Revenue | · | 4.3 | · | 2.1 | 1.2 | 3.5 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | · | · | · | -55.8% | -70.3% | -36.6% | · | -16.0% | -20.9% | -12.2% | · | -45.7% | -32.0% | -39.4% | -25.9% | -21.7% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $264M | $164M | $1M | · | · |
| Faaliyet Kâr Marjı % | -153.1% | -240.9% | -38735.0% | · | · |
| Net Gelir | $-391M | $-372M | $-444M | $-396M | $-342M |
| Seyreltilmiş Hisse Başı Kâr | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.0 | · | · | · | · |
| Cari Oran | 3.2 | 3.7 | 2.8 | 5.2 | 5.7 |
| Cari Oran | 2.7 | 3.2 | 2.5 | 5.2 | 5.7 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-336M | $-364M | $-384M | $-313M | $-266M |
Kurumsal Sahipler (13F) 316 dosya · $1.3B toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
316
Tutulan Değer
$1.3B
Yeni pozisyonlar
44
Çıkan pozisyonlar
35
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 44 (-27 önceki Ç'ye göre) | 35 (+1 önceki Ç'ye göre) | 134 (+11 önceki Ç'ye göre) | 63 (+1 önceki Ç'ye göre) | +19.7M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BlackRock, Inc. | $153.743.956 | 36.957.681 | 12,11% | Hisse senetleri |
| MHR FUND MANAGEMENT LLC | $120.503.148 | 28.967.103 | 9,49% | Hisse senetleri |
| STATE STREET CORP | $101.829.595 | 24.478.268 | 8,02% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $79.084.500 | 19.010.697 | 6,23% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $75.729.672 | 18.204.248 | 5,96% | Hisse senetleri |
| VANGUARD GROUP INC | $74.275.326 | 27.207.079 | 5,85% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $59.858.236 | 14.388.999 | 4,71% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $42.958.080 | 10.324.826 | 3,38% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $35.467.823 | 8.525.919 | 2,79% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $26.877.382 | 6.460.449 | 2,12% | Hisse senetleri |
| Palo Alto Investors LP | $22.032.229 | 5.296.209 | 1,73% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $21.200.749 | 5.096.334 | 1,67% | Hisse senetleri |
| Nuveen, LLC | $20.787.985 | 4.997.112 | 1,64% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $20.773.309 | 4.993.584 | 1,64% | Hisse senetleri |
| MORGAN STANLEY | $20.743.678 | 4.986.461 | 1,63% | Hisse senetleri |
| JUPITER ASSET MANAGEMENT LTD | $18.865.933 | 4.535.080 | 1,49% | Hisse senetleri |
| JANE STREET GROUP, LLC | $18.278.428 | 4.393.853 | 1,44% | Hisse senetleri |
| NORTHERN TRUST CORP | $17.281.471 | 4.154.200 | 1,36% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $16.097.468 | 3.869.584 | 1,27% | Hisse senetleri |
| WELLS FARGO & COMPANY/MN | $13.505.594 | 3.246.537 | 1,06% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $13.393.769 | 3.219.656 | 1,05% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.097.216 | 2.667.600 | 0,87% | Alım opsiyonu |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.052.038 | 2.656.740 | 0,87% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $10.578.372 | 2.542.878 | 0,83% | Hisse senetleri |
| JPMORGAN CHASE & CO | $10.237.104 | 2.431.616 | 0,81% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $9.953.632 | 2.392.700 | 0,78% | Satım opsiyonu |
| D. E. Shaw & Co., Inc. | $8.915.437 | 2.143.134 | 0,70% | Hisse senetleri |
| CITADEL ADVISORS LLC | $8.756.758 | 2.104.990 | 0,69% | Hisse senetleri |
| Long Focus Capital Management, LLC | $8.736.000 | 2.100.000 | 0,69% | Hisse senetleri |
| Orion Investment Co | $8.624.520 | 2.073.202 | 0,68% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $8.230.950 | 3.015.000 | 0,65% | Hisse senetleri |
| Xcelsior Advisor Partners LLC | $7.421.124 | 1.783.924 | 0,58% | Hisse senetleri |
| Rhenman & Partners Asset Management AB | $7.094.160 | 1.705.327 | 0,56% | Hisse senetleri |
| Knott David M Jr | $6.656.000 | 1.600.000 | 0,52% | Hisse senetleri |
| RICE HALL JAMES & ASSOCIATES, LLC | $6.405.734 | 1.539.840 | 0,50% | Hisse senetleri |
| B Group, Inc. | $6.240.000 | 1.500.000 | 0,49% | Hisse senetleri |
| Invenomic Capital Management LP | $6.167.595 | 1.482.595 | 0,49% | Hisse senetleri |
| Woodline Partners LP | $5.671.020 | 1.363.226 | 0,45% | Hisse senetleri |
| FMR LLC | $5.638.373 | 1.355.378 | 0,44% | Hisse senetleri |
| UBS Group AG | $5.373.323 | 1.291.664 | 0,42% | Hisse senetleri |
| Invesco Ltd. | $5.346.332 | 1.285.176 | 0,42% | Hisse senetleri |
| Bank of New York Mellon Corp | $4.834.325 | 1.162.097 | 0,38% | Hisse senetleri |
| Mirador Capital Partners LP | $4.493.998 | 1.080.288 | 0,35% | Hisse senetleri |
| Susquehanna Portfolio Strategies, LLC | $4.391.217 | 1.055.581 | 0,35% | Hisse senetleri |
| SECTOR GAMMA AS | $4.028.819 | 968.466 | 0,32% | Hisse senetleri |
| CITIGROUP INC | $3.669.669 | 882.132 | 0,29% | Hisse senetleri |
| DEUTSCHE BANK AG\ | $3.556.688 | 854.973 | 0,28% | Hisse senetleri |
| Jump Financial, LLC | $3.435.757 | 825.903 | 0,27% | Hisse senetleri |
| CITADEL ADVISORS LLC | $3.385.824 | 813.900 | 0,27% | Alım opsiyonu |
| JANE STREET GROUP, LLC | $3.037.216 | 730.100 | 0,24% | Alım opsiyonu |
Aktivistler ve %5+ sahipler 6 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Quogue Capital LLC, Wayne P. Rothbaum ×5 başvurular | 19 Mart 2024 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 11 Şubat 2015 | · | İlk başvuru | · | SEC |
| Bristol Investment Fund, Ltd., Bristol Capital, LLC ×4 başvurular | 20 Şubat 2014 | · | İlk başvuru | · | SEC |
| Robert T. Brooke ×2 başvurular | 12 Mayıs 2011 | · | İlk başvuru | · | SEC |
| Hamilton Atlantic | 05 Kasım 2010 | · | İlk başvuru | M&A / satış | SEC |
| Açıklanmayan raporlama kişisi | 29 Mart 2010 | · | İlk başvuru | M&A / satış | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 40 içeriden öğrenenler · 11 yöneticiler · 16 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Frederick G Vogt | Interim CEO & General Counsel | 08 Eylül 2026 M | 595.447 | 0 | 0 | $0 |
| Maria Fardis | President and CEO | 04 Ocak 2021 A | 298.786 | 0 | 0 | $0 |
| Paul Kessler | Chair,CEO, Pres., Pr.Acctg | 24 Temmuz 2013 A | 15.693.215 | 0 | 0 | $0 |
| Tony Cataldo | CEO, President | 06 Mayıs 2011 A | 3.000.000 | 0 | 0 | $0 |
| Jean-Marc Bellemin | Chief Financial Officer | 02 Haziran 2025 M | 60.529 | 0 | 0 | $0 |
| Timothy E Morris | Chief Financial Officer | 04 Mart 2019 A | · | 0 | 0 | $0 |
| Igor Bilinsky | Chief Operating Officer | 08 Eylül 2026 M | 142.074 | 0 | 0 | $0 |
| Noah Berkowitz | Chief Medical Officer | 30 Eylül 2026 A | · | 0 | 0 | $0 |
| Raj K. Puri | Chief Regulatory Officer | 08 Eylül 2026 M | 256.364 | 0 | 0 | $0 |
| Finckenstein Friedrich Graf | Chief Medical Officer | 05 Haziran 2026 M | 140.111 | 0 | 0 | $0 |
| Michael Swartzburg | Vice President, Finance (PAO) | 04 Ocak 2021 A | · | 0 | 0 | $0 |
| Iain D. Dukes | Yönetim kurulu üyesi | 16 Haziran 2026 A | 54.000 | 0 | 0 | $0 |
| Athena Countouriotis | Yönetim kurulu üyesi | 16 Haziran 2026 A | · | 0 | 0 | $0 |
| Ryan D Maynard | Yönetim kurulu üyesi | 16 Haziran 2026 A | 7.500 | 0 | 0 | $0 |
| Michael Weiser | Yönetim kurulu üyesi | 16 Haziran 2026 A | 112.632 | 0 | 0 | $0 |
| Wendy L Yarno | Yönetim kurulu üyesi | 13 Haziran 2025 A | · | 0 | 0 | $0 |
| Wayne P. Rothbaum | Yönetim kurulu üyesi | 01 Mart 2024 A | 28.067.333 | 0 | 0 | $0 |
| Merrill A Mcpeak | Yönetim kurulu üyesi | 01 Mart 2024 A | 320.150 | 0 | 0 | $0 |
| Wendy L Dixon | Yönetim kurulu üyesi | 10 Haziran 2022 A | · | 0 | 0 | $0 |
| David J Voyticky | Yönetim kurulu üyesi | 24 Temmuz 2013 A | 13.353.215 | 0 | 0 | $0 |
| Ayer Capital Management, LP | Yönetim kurulu üyesi | 22 Mayıs 2013 C | 560.401.150 | 0 | 0 | $0 |
| Martin Schroeder | Yönetim kurulu üyesi | 22 Ağustos 2011 P | 1.000.000 | 0 | 0 | $0 |
| Mark J Ahn | Yönetim kurulu üyesi | 26 Mayıs 2010 A | · | 0 | 0 | $0 |
| Bristol Investment Fund, Ltd. | 10% sahip | 06 Kasım 2014 S | 3.867.863 | 0 | 0 | $0 |
| Hamilton Atlantic | 10% sahip | 31 Mart 2010 J | 0 | 0 | 0 | $0 |
| Daniel Gordon Kirby | · | 10 Ağustos 2026 M | 154.511 | 0 | 0 | $0 |
| Corleen M. Roche | · | 06 Ağustos 2026 M | 28.757 | 0 | 0 | $0 |
| Jay Venkatesan | · | 01 Haziran 2017 A | · | 0 | 0 | $0 |
| Sanford Hillsberg | · | 01 Haziran 2017 A | 100.000 | 0 | 0 | $0 |
| Gregory T Schiffman | · | 14 Kasım 2016 A | · | 0 | 0 | $0 |
| Molly Henderson | · | 10 Haziran 2016 A | · | 0 | 0 | $0 |
| Michael Lotze | · | 28 Mart 2016 A | · | 0 | 0 | $0 |
| James G. Bender | · | 11 Mart 2016 A | 88.726 | 0 | 0 | $0 |
| Elma Hawkins | · | 11 Mart 2016 A | 176.567 | 0 | 0 | $0 |
| Steven A. Fischkoff | · | 04 Şubat 2016 A | · | 0 | 0 | $0 |
| Laszlo Radvanyi | · | 05 Aralık 2014 A | 180.000 | 0 | 0 | $0 |
| Michael D Handelman | · | 05 Aralık 2014 A | · | 0 | 0 | $0 |
| Manish Singh | · | 30 Aralık 2013 A | 2.546.000 | 0 | 0 | $0 |
| Richard Mckilligan | · | 29 Mart 2011 J | 1.220.016 | 0 | 0 | $0 |
| Robert T. Brooke | · | 25 Mart 2011 J | 4.440.008 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 37 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| PTH · Invesco Exchange-Traded Fund Trust | 4,88% | 987.622 SH | 02 Ekim 2026 | Günlük |
| IDNA · iShares Trust | 3,07% | 963.108 SH | 11 Eylül 2026 | Günlük |
| BBP · ETFis Series Trust I | 1,37% | 332.635 NS | 31 Temmuz 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,95% | 270.031 SH | 02 Ekim 2026 | Günlük |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,91% | 14.671 SH | 02 Ekim 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,45% | 841.048 SH | 02 Ekim 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,43% | 32.023 SH | 02 Ekim 2026 | Günlük |
| LABU · Direxion Shares ETF Trust | 0,41% | 492.493 NS | 31 Temmuz 2026 | N-PORT |
| IBB · iShares Trust | 0,23% | 2.961.520 SH | 11 Eylül 2026 | Günlük |
| PWS · Pacer Funds Trust | 0,11% | 6.729 NS | 31 Temmuz 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,11% | 346.628 SH | 19 Ağustos 2026 | Günlük |
| IWM · iShares Trust | 0,11% | 10.163.644 SH | 11 Eylül 2026 | Günlük |
| TECB · iShares Trust | 0,06% | 38.134 SH | 11 Eylül 2026 | Günlük |
| RSSL · Global X Funds | 0,05% | 190.525 NS | 31 Temmuz 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,05% | 261.797 SH | 19 Ağustos 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,05% | 2.290.247 SH | 19 Ağustos 2026 | Günlük |
| DXUV · Dimensional ETF Trust | 0,03% | 45.144 NS | 31 Temmuz 2026 | N-PORT |
| WSML · iShares Trust | 0,03% | 21.763 SH | 11 Eylül 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,03% | 962.767 NS | 31 Temmuz 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 166.388 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 4.303.944 SH | 19 Ağustos 2026 | Günlük |
| VBR · VANGUARD INDEX FUNDS | 0,02% | 3.089.380 SH | 19 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,02% | 1.053.780 SH | 19 Ağustos 2026 | Günlük |
| TILT · FlexShares Trust | 0,01% | 74.822 NS | 31 Temmuz 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,01% | 4.849.607 SH | 19 Ağustos 2026 | Günlük |
| DFAC · Dimensional ETF Trust | 0,01% | 1.049.483 NS | 31 Temmuz 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 63.899 NS | 31 Temmuz 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,01% | 28.098 NS | 31 Temmuz 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 146.278 NS | 31 Temmuz 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 510.942 SH | 11 Eylül 2026 | Günlük |
| IWV · iShares Trust | 0,00% | 106.978 SH | 11 Eylül 2026 | Günlük |
| DFUS · Dimensional ETF Trust | 0,00% | 125.583 NS | 31 Temmuz 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 13.489.795 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 32.806 SH | 19 Ağustos 2026 | Günlük |
| IWN · iShares Trust | · | 3.730.642 SH | 11 Eylül 2026 | Günlük |
| ISCB · iShares Trust | · | 15.580 SH | 11 Eylül 2026 | Günlük |
| ISCV · iShares Trust | · | 77.914 SH | 11 Eylül 2026 | Günlük |
IOVA Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 15 analist
AL
Medyan hedef
$13.00
-8,5%
3 20,0%
Güçlü Al
9 60,0%
Al
3 20,0%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
10 analist · 2026-09-30Ortalama hedef $12.40 -12,8%
Şimdi
Mevcut fiyat $14.21
Düşük$6.00
Ortalama$12.40
Yüksek$20.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| IOVA | $1.12B | -2.5 | 60.6% | -148.4% | -56.0% | · |
| IONS | $12.92B | -33.2 | · | · | -68.1% | · |
| IMVT | $5.07B | -9.0 | 229.2% | · | -73.7% | · |
| RYTM | $7.19B | -34.4 | 45.8% | -103.6% | -309.1% | · |
| GRAL | $3.45B | -7.7 | 17.2% | -277.5% | -16.7% | · |
| CGON | $3.35B | -20.0 | 254.7% | -3985.0% | -22.6% | · |
| SRRK | $4.78B | -13.4 | · | · | -157.9% | · |
| KOD | $1.73B | -6.5 | · | · | -202.0% | · |
| ORKA | $1.48B | -3.3 | · | · | -25.9% | · |
| COGT | $5.72B | -16.4 | · | · | -83.1% | · |
Son Haberler Bu şirketten bahseden son manşetler
Iovance Biotherapeutics (IOVA) Yıldızlarla Dolu 2. Çeyrek Sonrası %43 Yükseldi. Sırada Ne Var?
Yahoo Finance · 1 ay, 3 hafta önce
Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Small-Cap Stocks to Buy Now?
Yahoo Finance · 3 ay, 3 hafta önce
Chardan, Iovance'ın (IOVA) Hedef Fiyatını Düşürdü, Al Tavsiyesini Korudu
Yahoo Finance · 4 ay, 2 hafta önce
Iovance Biotherapeutics Q1 Kazanç Konuşması Özetleri
Yahoo Finance · 4 ay, 3 hafta önce
Analist Görüşü, Melanoma İlaçı Amtagvi'nin ABD Piyasasına Girişine Rampingen Iovance Biotherapeutics (IOVA) Hakkında Güçlü Kalıyor
Yahoo Finance · 6 ay, 1 hafta önce
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 6, 2026